Identification

Name
Triamterene
Accession Number
DB00384  (APRD00079)
Type
Small Molecule
Groups
Approved
Description

A pteridine that is used as a mild diuretic. [PubChem]

Structure
Thumb
Synonyms
  • 6-phenylpteridine-2,4,7-triamine
  • Teridin
  • Triamteren
  • Triamtérène
  • Triamterene
  • Triamtereno
  • Triamterenum
External IDs
NSC-77625 / SK&F 8542 / SK&F-8542
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DyreniumCapsule50 mg/1OralWell Spring Pharmaceutical Corporation1999-10-01Not applicableUs
DyreniumCapsule100 mg/1OralConcordia Pharmaceuticals, Inc1999-01-01Not applicableUs
DyreniumCapsule50 mg/1OralConcordia Pharmaceuticals, Inc1999-10-01Not applicableUs
DyreniumCapsule100 mg/1OralWell Spring Pharmaceutical Corporation1999-01-01Not applicableUs65197 0003 01 nlmimage10 2e45975c
DyreniumCapsule50 mg/1OralCarilion Materials Management1999-10-01Not applicableUs65197 0002 01 nlmimage10 3315999c
Dyrenium 100Tablet100 mgOralGlaxosmithkline Inc1992-12-312002-07-03Canada
Dyrenium 50Tablet50 mgOralGlaxosmithkline Inc1992-12-312002-07-03Canada
International/Other Brands
Diuteren (Kotobuki Seiyaku) / Dyrenium / Dytac (Mercury) / Riyazine (Ciiphar) / Triteren (Kyoto Yakuhin) / Urinis (Ying Yuan)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo TriazideTriamterene (50 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation1984-12-31Not applicableCanada
DyazideTriamterene (37.5 mg/1) + Hydrochlorothiazide (25 mg/1)CapsuleOralCardinal Health1994-03-30Not applicableUs00007 3650 22 nlmimage10 4c192669
DyazideTriamterene (37.5 mg/1) + Hydrochlorothiazide (25 mg/1)CapsuleOralMckesson Rxpak Inc1994-03-30Not applicableUs
DyazideTriamterene (37.5 mg/1) + Hydrochlorothiazide (25 mg/1)CapsuleOralGlaxosmithkline Inc1994-03-30Not applicableUs
Dyazide TabTriamterene (50 mg) + Hydrochlorothiazide (25 mg)TabletOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-312001-03-05Canada
MaxzideTriamterene (75 mg/1) + Hydrochlorothiazide (50 mg/1)TabletOralMylan Pharmaceuticals1988-05-13Not applicableUs
Maxzide-25Triamterene (37.5 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralMylan Pharmaceuticals1988-05-13Not applicableUs
Nu-triazide Tab 50 Mg/25 mgTriamterene (50 mg) + Hydrochlorothiazide (25 mg)TabletOralNu Pharm Inc1990-12-312012-09-04Canada
Penta-triamterene Hctz TabletsTriamterene (50 mg) + Hydrochlorothiazide (25 mg)TabletOralPentapharm Ltd.1999-07-122004-07-30Canada
Pro-triazideTriamterene (50 mg) + Hydrochlorothiazide (25 mg)TabletOralPro Doc Limitee1985-12-31Not applicableCanada
Categories
UNII
WS821Z52LQ
CAS number
396-01-0
Weight
Average: 253.2626
Monoisotopic: 253.107593387
Chemical Formula
C12H11N7
InChI Key
FNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
IUPAC Name
6-phenylpteridine-2,4,7-triamine
SMILES
NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.

Structured Indications
Pharmacodynamics

Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.

Mechanism of action

Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.

TargetActionsOrganism
AAmiloride-sensitive sodium channel subunit gamma
inhibitor
Human
AAmiloride-sensitive sodium channel subunit alpha
inhibitor
Human
AAmiloride-sensitive sodium channel subunit beta
inhibitor
Human
UAmiloride-sensitive sodium channel subunit delta
inhibitor
Human
Absorption

Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.

Volume of distribution
Not Available
Protein binding

55-67% (93% for the OH-TA-ester metabolite)

Metabolism

Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.

Route of elimination
Not Available
Half life

255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.

Clearance
  • 4.5 l/min [total plasma clearance]
  • 0.22 l/kg [renal plasma clearance]
Toxicity

In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Triamterene Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Triamterene can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Triamterene.Approved, Investigational
AcemetacinThe risk or severity of renal failure can be increased when Triamterene is combined with Acemetacin.Approved, Experimental, Investigational
AcetyldigitoxinThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.Approved
AcetyldigoxinThe therapeutic efficacy of Acetyldigoxin can be decreased when used in combination with Triamterene.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Triamterene.Approved
AlclofenacAlclofenac may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triamterene.Approved, Illicit
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Triamterene.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triamterene.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Triamterene.Illicit
Ammonium chlorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Ammonium chloride.Approved, Vet Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Triamterene.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Triamterene.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Triamterene.Approved
ApocyninApocynin may decrease the antihypertensive activities of Triamterene.Investigational
ApremilastApremilast may decrease the antihypertensive activities of Triamterene.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Triamterene.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Triamterene.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Triamterene.Approved
AzithromycinThe metabolism of Triamterene can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Triamterene.Approved, Investigational
BenazeprilTriamterene may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Triamterene.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Triamterene.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Triamterene.Withdrawn
BenzydamineBenzydamine may decrease the antihypertensive activities of Triamterene.Approved
BevoniumBevonium may decrease the antihypertensive activities of Triamterene.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Triamterene.Experimental, Illicit, Withdrawn
BortezomibThe metabolism of Triamterene can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacBromfenac may decrease the antihypertensive activities of Triamterene.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Triamterene.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Triamterene.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Triamterene.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Triamterene can be decreased when combined with Caffeine.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Triamterene.Approved
CandesartanCandesartan may increase the hyperkalemic activities of Triamterene.Experimental
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Triamterene.Approved
CandoxatrilTriamterene may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilTriamterene may increase the hyperkalemic activities of Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Triamterene.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triamterene.Illicit, Investigational, Vet Approved
CarprofenCarprofen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the antihypertensive activities of Triamterene.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
ChloroquineChloroquine may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Triamterene.Approved
CilazaprilTriamterene may increase the hyperkalemic activities of Cilazapril.Approved
CitalopramThe metabolism of Triamterene can be decreased when combined with Citalopram.Approved
ClonixinClonixin may decrease the antihypertensive activities of Triamterene.Approved
ClotrimazoleThe metabolism of Triamterene can be decreased when combined with Clotrimazole.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.Approved, Illicit
CurcuminCurcumin may decrease the antihypertensive activities of Triamterene.Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe therapeutic efficacy of Cymarin can be decreased when used in combination with Triamterene.Experimental
Cyproterone acetateThe serum concentration of Triamterene can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DeferasiroxThe serum concentration of Triamterene can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilTriamterene may increase the hyperkalemic activities of Delapril.Experimental
DeslanosideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triamterene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triamterene.Approved, Investigational
DiclofenacDiclofenac may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Triamterene.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Triamterene.Approved
DigitoxinThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.Approved, Investigational
DigoxinThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.Approved
Digoxin Immune Fab (Ovine)The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Triamterene.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triamterene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.Approved, Illicit
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Triamterene.Approved
DosulepinThe metabolism of Triamterene can be decreased when combined with Dosulepin.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triamterene.Experimental
DrospirenoneDrospirenone may increase the hyperkalemic activities of Triamterene.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Triamterene.Withdrawn
DuvelisibDuvelisib may decrease the antihypertensive activities of Triamterene.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Triamterene.Investigational
EnalaprilTriamterene may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatTriamterene may increase the hyperkalemic activities of Enalaprilat.Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Triamterene.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Triamterene.Approved
EprosartanEprosartan may increase the hyperkalemic activities of Triamterene.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Triamterene.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Triamterene.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Triamterene.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Triamterene.Approved, Investigational
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triamterene.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Triamterene.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Triamterene.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Triamterene.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Triamterene.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Triamterene.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Triamterene.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Triamterene.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Triamterene.Experimental
FimasartanFimasartan may increase the hyperkalemic activities of Triamterene.Approved, Investigational
FloctafenineFloctafenine may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Triamterene.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Triamterene.Experimental
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Triamterene.Approved, Investigational
FluvoxamineThe metabolism of Triamterene can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Triamterene.Experimental
FosinoprilTriamterene may increase the hyperkalemic activities of Fosinopril.Approved
GitoformateThe therapeutic efficacy of Gitoformate can be decreased when used in combination with Triamterene.Experimental
GuacetisalGuacetisal may decrease the antihypertensive activities of Triamterene.Experimental
HeparinHeparin may increase the hyperkalemic activities of Triamterene.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triamterene.Approved, Illicit, Investigational
HigenamineHigenamine may decrease the antihypertensive activities of Triamterene.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.Approved, Illicit
IbuprofenIbuprofen may decrease the antihypertensive activities of Triamterene.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Triamterene.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Triamterene.Approved
ImidaprilTriamterene may increase the hyperkalemic activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Triamterene.Experimental
IndobufenIndobufen may decrease the antihypertensive activities of Triamterene.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Triamterene.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Triamterene.Withdrawn
IrbesartanIrbesartan may increase the hyperkalemic activities of Triamterene.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Triamterene.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Triamterene.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triamterene.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Triamterene.Approved
Lanatoside CThe therapeutic efficacy of Lanatoside C can be decreased when used in combination with Triamterene.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.Approved
LidocaineThe metabolism of Triamterene can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilTriamterene may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Triamterene.Investigational
LobeglitazoneThe metabolism of Triamterene can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triamterene.Illicit
LonazolacLonazolac may decrease the antihypertensive activities of Triamterene.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Triamterene.Approved, Investigational
LosartanLosartan may increase the hyperkalemic activities of Triamterene.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Triamterene.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Triamterene.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Triamterene.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Triamterene.Experimental
MesalazineMesalazine may decrease the antihypertensive activities of Triamterene.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Triamterene.Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triamterene.Approved, Illicit
MetildigoxinThe therapeutic efficacy of Metildigoxin can be decreased when used in combination with Triamterene.Experimental
MexiletineThe metabolism of Triamterene can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Triamterene can be decreased when combined with Midostaurin.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Triamterene.Investigational
MoexiprilTriamterene may increase the hyperkalemic activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Triamterene.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Triamterene.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Triamterene.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Triamterene.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Triamterene.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Triamterene.Approved
NevirapineThe metabolism of Triamterene can be decreased when combined with Nevirapine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Triamterene.Experimental
NicorandilNicorandil may increase the hyperkalemic activities of Triamterene.Approved, Investigational
NifenazoneNifenazone may decrease the antihypertensive activities of Triamterene.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Triamterene.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Triamterene.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Triamterene.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triamterene.Approved, Illicit
OleandrinThe therapeutic efficacy of Oleandrin can be decreased when used in combination with Triamterene.Experimental, Investigational
OlmesartanOlmesartan may increase the hyperkalemic activities of Triamterene.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Triamterene.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Triamterene.Approved
OmapatrilatTriamterene may increase the hyperkalemic activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triamterene.Approved, Illicit
OrgoteinOrgotein may decrease the antihypertensive activities of Triamterene.Vet Approved
OsimertinibThe serum concentration of Triamterene can be decreased when it is combined with Osimertinib.Approved
OuabainThe therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Triamterene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
ParecoxibParecoxib may decrease the antihypertensive activities of Triamterene.Approved
ParthenolideParthenolide may decrease the antihypertensive activities of Triamterene.Investigational
Peginterferon alfa-2bThe serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.Approved, Vet Approved
PerindoprilTriamterene may increase the hyperkalemic activities of Perindopril.Approved
PeruvosideThe therapeutic efficacy of Peruvoside can be decreased when used in combination with Triamterene.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Triamterene.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Triamterene.Experimental
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Triamterene.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Triamterene.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Triamterene.Experimental, Investigational
ProglumetacinProglumetacin may decrease the antihypertensive activities of Triamterene.Experimental
PropacetamolPropacetamol may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Triamterene.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Triamterene.Experimental
ProscillaridinThe therapeutic efficacy of Proscillaridin can be decreased when used in combination with Triamterene.Experimental
PTC299PTC299 may decrease the antihypertensive activities of Triamterene.Investigational
QuinaprilTriamterene may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.Approved
RamiprilTriamterene may increase the hyperkalemic activities of Ramipril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.Approved
RescinnamineTriamterene may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Triamterene.Approved, Experimental, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Triamterene.Investigational, Withdrawn
RopiniroleThe metabolism of Triamterene can be decreased when combined with Ropinirole.Approved, Investigational
RucaparibThe metabolism of Triamterene can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilSacubitril may increase the hyperkalemic activities of Triamterene.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Triamterene.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Triamterene.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Triamterene.Experimental
SaralasinSaralasin may increase the hyperkalemic activities of Triamterene.Investigational
SemapimodSemapimod may decrease the antihypertensive activities of Triamterene.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Triamterene.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Triamterene.Investigational
SimeprevirThe metabolism of Triamterene can be decreased when combined with Simeprevir.Approved
Sodium phosphateTriamterene may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilTriamterene may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneTriamterene may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Triamterene.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Triamterene.Approved
SulindacSulindac may decrease the antihypertensive activities of Triamterene.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Triamterene.Experimental
TacrolimusThe risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Triamterene.Investigational
TasosartanTasosartan may increase the hyperkalemic activities of Triamterene.Approved
TelmisartanTelmisartan may increase the hyperkalemic activities of Triamterene.Approved, Investigational
TemocaprilTriamterene may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Triamterene.Experimental
Tenofovir disoproxilThe metabolism of Triamterene can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Triamterene.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Triamterene.Vet Approved
TeriflunomideThe serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Triamterene can be decreased when combined with Theophylline.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Triamterene.Approved
TiclopidineThe metabolism of Triamterene can be decreased when combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Triamterene.Experimental
TinoridineTinoridine may decrease the antihypertensive activities of Triamterene.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Triamterene.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Triamterene.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Triamterene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.Approved, Investigational
TrandolaprilTriamterene may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Triamterene.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Triamterene.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Triamterene.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Triamterene.Investigational, Withdrawn
ValsartanValsartan may increase the hyperkalemic activities of Triamterene.Approved, Investigational
VemurafenibThe serum concentration of Triamterene can be increased when it is combined with Vemurafenib.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Triamterene.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Triamterene.Approved, Investigational, Withdrawn
ZofenoprilTriamterene may increase the hyperkalemic activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Triamterene.Withdrawn
ZucapsaicinThe metabolism of Triamterene can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Frederic J. Nugent, John K. C. Yen, "Process for preparing the combination products of triamterene and hydrochlorothiazide." U.S. Patent US4804540, issued July, 1987.

US4804540
General References
  1. Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. [PubMed:6628507]
External Links
Human Metabolome Database
HMDB0001940
KEGG Drug
D00386
PubChem Compound
5546
PubChem Substance
46507623
ChemSpider
5345
BindingDB
6644
ChEBI
9671
ChEMBL
CHEMBL585
Therapeutic Targets Database
DAP000575
PharmGKB
PA451752
IUPHAR
4329
Guide to Pharmacology
GtP Drug Page
HET
DX2
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Triamterene
ATC Codes
C03DB02 — Triamterene
AHFS Codes
  • 40:28.16 — Potassium-sparing Diuretics
PDB Entries
3jq7
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedNot AvailableCardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Arrest / Heart Diseases / High Blood Pressure (Hypertension)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentProteinuria1
Not AvailableUnknown StatusBasic ScienceDiabetic Nephropathies / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Wellspring pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral50 mg/1
TabletOral100 mg
TabletOral50 mg
CapsuleOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)316 °CPhysProp
water solubility48.2 mg/LNot Available
logP0.98HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.963 mg/mLALOGPS
logP1.21ALOGPS
logP1.11ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)3.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity75.13 m3·mol-1ChemAxon
Polarizability25.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8735
Caco-2 permeable+0.7017
P-glycoprotein substrateNon-substrate0.6269
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8437
CYP450 2C9 substrateNon-substrate0.8949
CYP450 2D6 substrateNon-substrate0.8892
CYP450 3A4 substrateNon-substrate0.7542
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6161
Ames testNon AMES toxic0.8934
CarcinogenicityNon-carcinogens0.9092
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.7706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-0090000000-c8bbcf103f5a3fdfebb5
MS/MS Spectrum - CI-B (Unknown) , PositiveLC-MS/MSsplash10-0udi-0090000000-c8bbcf103f5a3fdfebb5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udr-0090000000-007b38b2c4832f349909
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0590000000-b0551f41584c039101f6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kf-0910000000-6428faa965a39a470ea5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-c1e38db82ca2bfb168b7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-e0b752d624dade8793ef
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-4c12cffcdf72d196b590
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f79-0190000000-e63d14e64b8206d5c635
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f79-0970000000-a69efa072a4b5fca0463
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uxu-0910000000-f8ece9e1491b71df0c70
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uxu-3900000000-946796a2530a51263ccd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f79-9600000000-59b671ef134dd8106331
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gw0-9200000000-3451a9c6dc2b3f4b6e3b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0190000000-425707e7729440a5bdb4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0190000000-32f8b6872d5877d00316
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form pyrimido(4,5-b)pyrazine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pteridines and derivatives
Sub Class
Not Available
Direct Parent
Pteridines and derivatives
Alternative Parents
Aminopyrimidines and derivatives / Aminopyrazines / Imidolactams / Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Pteridine / Aminopyrazine / Aminopyrimidine / Monocyclic benzene moiety / Pyrazine / Pyrimidine / Benzenoid / Imidolactam / Heteroaromatic compound / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ww domain binding
Specific Function
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical...
Gene Name
SCNN1G
Uniprot ID
P51170
Uniprot Name
Amiloride-sensitive sodium channel subunit gamma
Molecular Weight
74269.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214]
  4. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124]
  5. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ww domain binding
Specific Function
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical...
Gene Name
SCNN1A
Uniprot ID
P37088
Uniprot Name
Amiloride-sensitive sodium channel subunit alpha
Molecular Weight
75703.08 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ww domain binding
Specific Function
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical...
Gene Name
SCNN1B
Uniprot ID
P51168
Uniprot Name
Amiloride-sensitive sodium channel subunit beta
Molecular Weight
72658.485 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ligand-gated sodium channel activity
Specific Function
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical...
Gene Name
SCNN1D
Uniprot ID
P51172
Uniprot Name
Amiloride-sensitive sodium channel subunit delta
Molecular Weight
70214.195 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:47